1. Orforglipron is an oral GLP-1 receptor agonist.
2. It significantly lowers blood sugar and aids in weight loss.
3. The 40-week trial had 559 participants.
4. Most achieved HbA1c < 7%.
5. Common side effects were gastrointestinal.
6. No severe hypoglycemia cases reported.
7. The trial was funded by Eli Lilly.
8. Longer-term studies are needed for sustained outcome evaluation.

Source: The New England Journal of Medicine